PerkinElmer experiences growth during 2010 fiscal year

PerkinElmer has published its financial report for the 2010 full-year period, highlighting a number of growth trends and positive developments.

The science company's continuing operations generated $1.7 billion (1.05 billion pounds), up by ten percent year-on-year, with both its human health and environmental health divisions benefiting from this growth.

It was also able to reinforce its future positioning by completing the divesture of its non-core illumination and detection solutions unit, resulting in a pre-tax gain of $315.3 million in the fourth quarter.

PerkinElmer now expects to achieve further organic revenue growth in the mid-single digit range in the coming fiscal year.

Robert Friel, chairman and chief executive officer of the firm, said: "We will continue to remain focused on increasing the growth profile of the company and employing a dedicated approach to improving our operating margins while investing in new technologies, software and services."

Last week, the company announced that its family cord blood banking business ViaCord has released its 200th umbilical cord blood unit for use in stem cell treatment.